Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia (PRISE)

July 13, 2026 updated by: Brainfarma Industria Química e Farmacêutica S/A

A Phase III, Multicenter, Randomized, Double-blind, Double-dummy, Controlled, Parallel-group, Non-inferiority Clinical Trial to Evaluate the Efficacy and Safety of Extended-release Pregabalin Tablets Compared With Immediate-release Pregabalin Tablets, in the Relief of Neuropathic Pain in Participants With Diabetic Peripheral Neuropathy or Postherpetic Neuralgia.

Extended-release Pregabalin for the Treatment of Neuropathic Pain in Patients With Diabetic Peripheral Neuropathy and Postherpetic Neuralgia

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

348

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • Brazil
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brazil, 41680430
        • Recruiting
        • Cpec Obras Sociais Irmã Dulce
        • Contact:
        • Principal Investigator:
          • Edson D. M. Júnior, Epidemiologist
    • Minas Gerais
      • Belo Horizonte, Minas Gerais, Brazil, 30575180
        • Recruiting
        • Instituto Anima de Extensão Universitária - Unibh
        • Contact:
        • Principal Investigator:
          • Dayane R. F. C, Neurology Residency
      • Vespasiano, Minas Gerais, Brazil, 33200664
        • Recruiting
        • Centro de Ensino Superior de Vespasiano
        • Contact:
        • Principal Investigator:
          • Fernanda C Perreiras, General/Surgical Oncologist
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brazil, 59076000
        • Recruiting
        • Apec Sociedade Potiguar de Educação E Cultura
        • Contact:
        • Principal Investigator:
          • Marcos L Freitas, Neurologist
    • Rio de Janeiro
      • Rio de Janeiro, Rio de Janeiro, Brazil, 20231092
        • Recruiting
        • Instituto Estadual Do Cerebro Paulo Niemeyer
        • Contact:
        • Principal Investigator:
          • Luiz E. A. Wildemberg, Endocrinologist
    • Santa Catarina
      • Joinville, Santa Catarina, Brazil, 89202190
        • Recruiting
        • Clinica Neurologica E Neurocirurgica de Joinville
        • Contact:
        • Principal Investigator:
          • Alexandre L Longo, Neurologist
      • Palhoça, Santa Catarina, Brazil, 88137270
        • Recruiting
        • Instituto Anima de Extensão Universitária - Unisul
        • Contact:
        • Principal Investigator:
          • Alexandre C Buffon, Anesthesiologist
    • Sergipe
      • Aracaju, Sergipe, Brazil, 49055480
        • Recruiting
        • Fundação de Beneficência Hospital de Cirurgia
        • Contact:
        • Principal Investigator:
          • Alex V. C. França, Gastroenterologist
      • Aracaju, Sergipe, Brazil, 49072720
        • Recruiting
        • Associação Aracajuana Hospital Santa Isabel
        • Contact:
        • Principal Investigator:
          • Alex V. C. França, Gastroenterologist
      • Aracaju, Sergipe, Brazil, 49075000
        • Recruiting
        • Newdata Clinical Research
        • Contact:
        • Principal Investigator:
          • Alex V. C. França, Gastroenterologist
    • São Paulo
      • Bragança Paulista, São Paulo, Brazil, 12916900
        • Recruiting
        • Casa de Nossa Senhora Da Paz Ação Social Franciscana
        • Contact:
        • Principal Investigator:
          • Rafaella S. D. Beltrame, Intensive care
      • Campinas, São Paulo, Brazil, 1308756
        • Recruiting
        • Synvia Campinas
        • Contact:
        • Principal Investigator:
          • Ana Lígia G. M. Germano, Endocrinologist
      • Campinas, São Paulo, Brazil, 13092108
        • Recruiting
        • Trialstar Campinas
        • Contact:
        • Principal Investigator:
          • Márcia S Carvalho, Endocrinologist
      • São Paulo, São Paulo, Brazil, 01139000
        • Recruiting
        • Synvia Clinical Barra Funda
        • Contact:
        • Principal Investigator:
          • Sara C Siqueira, Endocrinologist
      • São Paulo, São Paulo, Brazil, 03164000
        • Recruiting
        • Iscp Sociedade Educacional
        • Contact:
        • Principal Investigator:
          • Matheus A Silva, Neurologist

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

The following criteria must be met for a participant to be included in the study:

  1. Participants of either sex, aged 18 to 75 years.
  2. Be able to understand and agree to participate in the study, undergo the procedures, and attend the visits, as indicated by signing the informed consent form approved by the CEP/Conep System.

  3. Have a diagnosis of peripheral neuropathic pain associated with:

    • diabetes mellitus (type 1 or 2), with glycated hemoglobin (HbA1c) levels ≤ 11%, documented symptoms of peripheral diabetic neuropathy for at least 6 months, and use of medication for glycemic control at a stable dose for at least 30 days.
    • postherpetic neuralgia, with pain symptoms for at least 3 months following a skin rash due to an acute episode of herpes zoster.
  4. Presence of neuropathic pain, with an intensity of ≥ 4 on the 11-point DPRS numerical scale (from 0 "no pain" to 10 "worst possible pain"‡). ‡ Pain intensity ≥ 4 will be confirmed at the initial visit (IV); during the screening/randomization visit, Participant Diary No. 1 containing the DPRS scales will be provided, in which the participant will record pain intensity daily upon waking and at the end of the day for 7 days (±2 days). The mean value for pain intensity recorded during the Screening/Randomization Phase will be used to confirm eligibility at the initial visit (IV).

  5. Participants who are unable to become pregnant (postmenopausal women, defined as 12 months or more of amenorrhea, or who have undergone surgical sterilization*; and men who have undergone vasectomy**) OR participants of reproductive potential who agree to use a reliable method of contraception***.

    • Female sterilization (undergoing bilateral surgical oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least 6 weeks prior to administration of the investigational drug.

      • Male sterilization at least 6 months prior to screening. *** If the participant is of childbearing age and decides to participate in the study, they must use or request that their partner use a safe contraceptive method. A safe contraceptive method is defined as the use of at least one of the following: condoms, a diaphragm, and/or a hormonal method (estrogenic and/or progestogenic) in the form of medication, including oral, vaginal, injectable, transdermal, and intrauterine devices. Only participants who expressly declare themselves exempt from the risk of pregnancy-whether because they do not engage in sexual activity or because they engage in it in a non-reproductive manner-will have the right to participate in the study without the mandatory use of contraceptives. Examples include participants who have undergone a vasectomy, those with an infertile partner, or those practicing total heterosexual abstinence.

The decision regarding the best contraceptive method to use will be made jointly by the physician and the study participant. If there are any costs involved, the chosen contraceptive method will be provided by the sponsor free of charge for as long as necessary. In addition, condoms with spermicide will be provided to participants at all study visits, when applicable.

Exclusion Criteria:

A positive response to any of the following criteria will exclude the participant from the study:

  1. The presence of pain unrelated to the primary diagnosis of diabetic peripheral neuropathy or postherpetic neuralgia that could interfere with the evaluation.
  2. Any skin condition that potentially alters sensation in the affected dermatome or area of neuropathic involvement, which could interfere with the assessment.
  3. Having undergone neurosurgical therapy for the treatment of neuropathy.
  4. Current use, or use within the past 7 days, of nerve block therapy and/or medications commonly used to treat neuropathic pain (e.g., benzodiazepines, skeletal muscle relaxants, capsaicin, local anesthetics, opioids, memantine), antiepileptic drugs (e.g., carbamazepine, clonazepam, phenytoin, valproic acid, lamotrigine, topiramate, gabapentin), antidepressants (e.g., tricyclics, serotonin reuptake inhibitors, venlafaxine), and potential neurotoxins (e.g., hydroxychloroquine, deferoxamine, thioridazine, vigabatrin).
  5. History of treatment failure or hypersensitivity to pregabalin or gabapentin.
  6. History of neoplastic disease within the past 2 years (excluding basal cell carcinoma), neurological disease, unstable heart disease, psychiatric conditions (particularly suicidal ideation), and/or infection with hepatitis B, hepatitis C, or HIV.
  7. Current laboratory abnormalities in liver enzymes (elevated AST and/or ALT 2.5 times the upper limit of the reference range) and/or renal insufficiency (glomerular filtration rate < 60 mL/min/1.73 m²).
  8. History of illicit drug abuse in the past 2 years.

  9. History of alcoholism (average alcohol intake exceeding 3 standard drinks* per day or more than 7 standard drinks per week for women, and exceeding 4 standard drinks per day or more than 14 standard drinks per week for men) in the past 2 years.

    * A standard drink is: a can of regular beer (330 mL at 4%); a shot of distilled spirits (30 mL at 40%); a glass of wine or a small glass of sherry (100 mL at 12% or 70 mL at 18%); a small glass of liqueur or similar (50 mL at 25%) (53).

  10. Being pregnant, breastfeeding, or intending to become pregnant during the study period.
  11. Having participated in clinical studies in the past 12 (twelve) months, unless there may be a direct benefit to the study participant, at the investigator's discretion.
  12. Having any condition that prevents participation, at the investigator's discretion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pregabalin XR: Extended-release pregabalin
Pregabalin XR: will receive extended-release pregabalin tablets at an initial dose of 82.5 mg once daily (during the first week for titration). The dose may be adjusted every 7 days during the first 4 weeks of treatment, up to a maximum of 660 mg once daily. In addition, the experimental group may receive a placebo twice daily.
Drug: Experimental: Pregabalin XR
Pregabalin XR: extended-release tablet, with an initial dose of 82.5 mg once daily. The dose may be adjusted every 7 days during the first 4 weeks of treatment, up to a maximum of 660 mg once daily. In addition, the experimental group will receive a placebo twice daily.
Drug: experimental placebo
experimental placebo
Active Comparator: Dorene Tabs: Immediate-release pregabalin
Dorene Tabs: will receive immediate-release pregabalin tablets (Dorene Tabs) at a starting dose of 75 mg twice daily. The dose may be adjusted every 7 days during the first 4 weeks of treatment, up to a maximum of 300 mg twice daily. In addition, the comparison group will receive a placebo once daily.
Drug: Comparator placebo
Comparator placebo
Drug: Comparator: Dorene Tabs
Pregabalin immediate-release tablets, at an initial dose of 75 mg twice daily. The dose may be adjusted every 7 days during the first 4 weeks of treatment, up to a maximum of 300 mg twice daily. In addition, the comparator group will receive a placebo once daily.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in the mean pain intensity score 16 weeks after the start of treatment, compared to baseline
Time Frame: 16 weeks

Difference in the mean pain intensity score 16 weeks after the start of treatment, compared to baseline, between the study drug and the comparator, as measured by the 11-point DPRS (Daily Pain Rating Scale) (ranging from 0 "no pain" to 10 "worst possible pain").

Participants completed the baseline scale at the research center and filled it out daily at home until visit V8, twice a day. The average number of scales will be calculated by dividing the number of scales completed by the number of days on which they were completed.
16 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To assess improvement in neuropathic pain during treatment.
Time Frame: 1 to 12 weeks
Difference in the mean pain intensity score at 1, 4, 8, and 12 weeks after the start of treatment, compared to baseline, between the experimental drug and the comparator, as measured by the 11-point DPRS scale.
1 to 12 weeks
To assess the proportion of participants who experienced significant improvement in neuropathic pain during and at the end of treatment.
Time Frame: 1 to 16 weeks
Difference in the mean total pain score at 1, 4, 8, 12, and 16 weeks after the start of treatment, compared to baseline, between the experimental drug and the comparator, as measured by the SF-MPQ (Short Form - McGill Pain Questionnaire).
1 to 16 weeks
To assess improvements in the impact of neuropathic pain on sleep, quality of life, and symptoms of anxiety and depression during and at the end of treatment.
Time Frame: 1 to 16 weeks

Proportion of participants with a ≥ 30% reduction in pain intensity at 1, 4, 8, 12, and 16 weeks after the start of treatment, compared to baseline, between the study drug and the comparator, as measured by the 11-point DPRS scale. Difference in the mean score for pain interference with sleep at 4, 8, 12, and 16 weeks after the start of treatment, relative to baseline, between the study drug and the comparator, as measured by the 11-point DSIS (Daily Sleep Interference Scale) (ranging from 0 "pain did not interfere with sleep" to 10 "pain completely interfered with sleep").

Difference in quality of life at 4, 8, 12, and 16 weeks after the start of treatment, compared to baseline, between the experimental drug and the comparator, as measured by the WHOQoL-BREF (World Health Organization Quality of Life Scale).

Difference in anxiety and depression symptoms at 4, 8, 12, and 16 weeks after the start of treatment, compared to baseline, between the experimental drug and the comparator.
1 to 16 weeks
Assess the participant's overall perception of change at the end of treatment.
Time Frame: Week 16
Proportion of participants who rated their clinical condition as "much better," "moderately better," "slightly better," "no change," "slightly worse," "moderately worse," and "much worse," using the PGIC (Patient Global Impression of Change) scale, when comparing the experimental drug to the comparator 16 weeks after the start of treatment.
Week 16
Evaluate the use of rescue medication.
Time Frame: 1 to 16 weeks.
Proportion of participants who used rescue medication, frequency of use, dose, and duration, comparing the experimental medication with the comparator.
1 to 16 weeks.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety Outcome: To evaluate the safety of extended-release pregabalin tablets compared with immediate-release pregabalin tablets in participants with diabetic neuropathy or postherpetic neuralgia.
Time Frame: 19 weeks.
Incidence rate of serious and non-serious adverse events-both related and unrelated-by treatment group throughout the clinical trial, based on an analysis of data obtained from clinical and physical examinations and laboratory tests.
19 weeks.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Brainfarma Industria Química e Farmacêutica S/A

Investigators

  • Principal Investigator: Mariana Ferreira, Sports Nutrition, A2Z CLINICAL - CENTRO DE PESQUISA CLÍNICA, Valinhos, São Paulo 13271130

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 18, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

June 18, 2026

First Submitted That Met QC Criteria

July 13, 2026

First Posted (Actual)

July 20, 2026

Study Record Updates

Last Update Posted (Actual)

July 20, 2026

Last Update Submitted That Met QC Criteria

July 13, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HYP008-24

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neuropathic Pain

Clinical Trials on Comparator placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe